Biomedical Materials* (*Biomed. Mater.*)2012ReviewNon-viral Gene Delivery
Not Fully Listed In The Supplied File; Corresponding Authors Are Isaac Ojea ([email protected]) And Victor Puntes ([email protected])
Viral vectors give high gene-transfer efficiency but carry risks of immunogenicity, oncogenic transformation, limited cargo capacity, and manufacturing difficulty. Nonviral nanocarriers are safer and cheaper alternatives, but they still suffer from low transfection efficiency because of extracellular and…
Read the article →PNAS2012ResearchNon-viral Gene Delivery
David N. Nguyen, Kerry P. Mahon, Ghania Chikh, Phillip Kim, Hattie Chung, Alain P. Vicari, Kevin T. Love, Michael Goldberg, Steve Chen, Arthur M. Krieg, Jianzhu Chen, Robert Langer, Daniel G. Anderson
TLR7/8 agonists are promising vaccine adjuvants and antivirals, but RNA agonists are unstable and small-molecule agonists cause systemic toxicity. A delivery system specifically designed to deliver immunostimulatory RNA (isRNA) to TLR-expressing cells could enable safer and more localised innate immune activation. 14…
Read the article →Small2012ResearchNon-viral Gene Delivery
Nupura S. Bhise, Ron B. Shmueli, Jose Gonzalez, Jordan J. Green
Non-viral polymeric nanoparticles are promising for gene therapy and stem cell reprogramming, but the number of plasmids complexed per particle affects transfection efficiency and co-delivery of multiple plasmids. Existing methods for quantifying plasmids per particle have significant drawbacks, and few studies have…
Read the article →Molecular Pharmaceutics (inferred from known publication record; journal name not explicitly stated in supplied file)2012ResearchNon-viral Gene Delivery
Joel C. Sunshine, Daniel Y. Peng, Jordan J. Green
Non-viral gene delivery requires a better understanding of which polymer properties enable nanoparticles to overcome intracellular barriers. Poly(beta-amino ester)s (PBAEs) are promising, but the mechanisms behind their effectiveness—especially the roles of buffering capacity, degradation rate, and end-group…
Read the article →PLoS ONE2012ResearchNon-viral Gene Delivery
Sunshine, J. C., Sunshine, S. B., Bhutto, I., Handa, J. T., & Green, J. J. (2012).
Retinal pigment epithelial (RPE) cells are difficult to transfect, and existing nonviral reagents achieve only low efficiency in vitro. Improved nonviral gene delivery to RPE could benefit both laboratory studies and ocular gene therapy. Lead in vitro efficacy: B5-S5-E7 at 60 w/w transfected 44 ± 5% of ARPE-19 cells…
Read the article →Chemical Society Reviews2012ReviewDrug Delivery
Samal, S. K.; Dash, M.; Van Vlierberghe, S.; Kaplan, D. L.; Chiellini, E.; Van Blitterswijk, C.; Moroni, L.; Dubruel, P
Cationic polymers are widely studied as non-viral gene delivery vectors, but their therapeutic potential extends well beyond gene delivery. This review addresses the need for a broader overview of cationic polymers — their synthesis, modification, bioactive properties, architectures, and applications in drug…
Read the article →Journal of Controlled Release2012ReviewDrug Delivery
Fabienne Danhier, Eduardo Ansorena, Joana M. Silva, Regis Coco, Aude Le Breton, Véronique Préat
PLGA is one of the most successfully developed biodegradable polymers, with FDA and EMA approval for parenteral drug delivery, but a comprehensive overview linking its formulation methods, physicochemical pitfalls, targeting strategies, and applications across multiple diseases was needed. This review presents why…
Read the article →Pharmaceutical Research2011ReviewNon-viral Gene Delivery
Wei-Yun Sheng, Leaf Huang
The immune system can recognise and kill pre-cancer and cancer cells, but surviving tumour cells learn to escape immune surveillance after immunoselection. Cancer immunotherapy aims to overcome these escape mechanisms. Nanomedicine offers tools—nanodiagnostics and nanobiopharmaceuticals—to deliver antigens…
Read the article →Proceedings of the National Academy of Sciences of the United States of America (PNAS)2011ResearchDrug Delivery
Che-Ming J. Hu, Li Zhang, Santosh Aryal, Connie Cheung, Ronnie H. Fang, Liangfang Zhang
Long-circulating nanoparticles are needed for sustained systemic drug delivery, but PEGylation—the current stealth gold standard—can face anti-PEG immune responses. A top-down biomimetic approach using natural erythrocyte membranes could better mimic red blood cells (RBCs), nature’s long-circulating carriers, while…
Read the article →Nanomedicine: Nanotechnology, Biology, and Medicine2011ResearchNon-viral Gene Delivery
Shashi Prasad, Virginia Cody, Jennifer K. Saucier-Sawyer, W. Mark Saltzman, Clarence T. Sasaki, Richard L. Edelson, Martin A. Birchall, Douglas J. Hanlon
Efficient antigen delivery remains a major challenge for dendritic cell (DC)-based immunotherapy of solid-organ malignancies. Soluble tumour lysates suffer from instability, poor DC internalisation, and inefficient cross-presentation to cytotoxic T lymphocytes. PLGA nanoparticles may protect antigens, improve…
Read the article →International Journal of Nanomedicine (Dove Press open-access article; exact citation details not fully provided in the 2011ResearchNon-viral Gene Delivery
Stephany Y. Tzeng, Peter H. Yang, Warren L. Grayson, Jordan J. Green
Human umbilical vein endothelial cells (HUVECs) are relevant to tissue engineering, cancer therapy, and angiogenesis-related diseases. Non-viral vectors are safer than viruses but often less efficient. Biodegradable poly(ester amine) (PEA) and poly(amido amine) (PAA) nanoparticles were developed and screened for…
Read the article →Pharmaceutical Research2011ResearchNon-viral Gene Delivery
Samar Hamdy, Azita Haddadi, Anooshirvan Shayeqanpour, John Samuel, Afsaneh Lavasanifar
Mannosylation of vaccine formulations is a promising strategy to target antigens to the mannose receptor (MR) on dendritic cells (DCs), potentially improving antigen uptake, processing, and presentation. While PLGA nanoparticles (NPs) are established vaccine delivery vehicles, the effect of chemical conjugation of…
Read the article →Biomaterials2011ResearchNon-viral Gene Delivery
Stephany Y. Tzeng, Hugo Guerrero‐cazares, Elliott E. Martinez, Joel C. Sunshine, Alfredo Quiñones‐hinojosa, Jordan J. Green
Glioblastoma (GB) has poor survival and current therapies are insufficient. Viral gene therapy carries safety risks, while nonviral vectors often lack efficiency and practical storage stability. PBAEs had shown high transfection and low toxicity in other cell types but had not been tested in primary brain tumour…
Read the article →2011ReviewNon-viral Gene Delivery
Chou Lyt, Ming K, Chan Wcw.
Nanoparticles (NPs) are increasingly used as contrast agents, therapeutics, and delivery vehicles, but their effective delivery into cells and to specific subcellular organelles remains a major challenge. The review addresses fundamental barriers to intracellular NP delivery—plasma membrane, endosomal entrapment…
Read the article →Polymers2011ReviewDrug Delivery
Hirenkumar K. Makadia And Steven J. Siegel
PLGA has become one of the most attractive biodegradable polymers for drug delivery and tissue engineering, but its degradation and drug-release behaviour depend on many interconnected variables—polymer composition, molecular weight, crystallinity, device geometry, fabrication method, and drug type. A consolidated…
Read the article →Acta Pharmacologica Sinica2010ResearchNon-viral Gene Delivery
Jian Li, Ying-Zi He, Wen Li, Yun-Zhen Shen, Yu-Ru Li, Yun-Feng Wang
Non-viral gene delivery systems offer advantages in safety and ease of preparation over viral vectors, but suffer from limited transfection efficiency. While polymer-lipid hybrid nanoparticles (PLN) have shown promise as non-viral vectors, the incorporation of PEGylated lipids to enhance circulation time and…
Read the article →Proceedings of the National Academy of Sciences of the United States of America2010ResearchNon-viral Gene Delivery
Kevin T. Love, Kerry P. Mahon, Christopher G. Levins, Kathryn A. Whitehead, William Querbes, J. Robert Dorkin, June Qin, William Cantley, Liu Liang Qin, Timothy Racie, Maria Frank-Kamenetsky, Ka Ning Yip, Rene Alvarez, Dinah W. Y. Sah, Antonin De Fougerolles, Kevin Fitzgerald, Victor Koteliansky, Ak
Existing siRNA delivery systems required high doses (1 mg/kg) for hepatic gene silencing. A more potent, well-tolerated lipid-like delivery material was needed to enable low-dose RNAi therapeutics and multi-gene silencing in vivo. C12-200 enabled Factor VII silencing at doses below 0.01 mg/kg in mice, 100-fold more…
Read the article →Proceedings of the National Academy of Sciences of the United States of America (PNAS)2010ResearchNon-viral Gene Delivery
Fan Yang, Seung-Woo Cho, Sun Mi Son, Said R. Bogatyrev, Deepika Singh, Jordan J. Green, Ying Mei, Sohyun Park, Suk Ho Bhang, Byung-Soo Kim, Robert Langer, Daniel G. Anderson
Stem cell therapy for angiogenesis is limited by insufficient expression of angiogenic factors and poor cell viability after transplantation. Viral gene delivery raises safety concerns, while non-viral methods often suffer from low transfection efficiency and toxicity. A safe, efficient, biodegradable polymeric…
Read the article →Biomaterials2010ResearchNon-viral Gene Delivery
Nupura S. Bhise, Ryan S. Gray, Joel C. Sunshine, Soe Htet, Andrew J. Ewald, Jordan J. Green
Non-viral gene delivery vectors are safer alternatives to viral vectors but often suffer from low transfection efficiency, especially in hard-to-transfect primary cells and 3-D tissue models. There is a need to understand how small changes in polymer structure—specifically terminal functionalisation and molecular…
Read the article →Clinical & Experimental Metastasis2010ResearchNon-viral Gene Delivery
Seo Sh, Han Hd, Noh Kh, Kim Tw, Son Sw
Chemo-immunotherapy combinations are limited by systemic immunotoxicity from cancer drugs and rapid clearance of low-molecular-weight drugs after intratumoral injection. A local, biodegradable delivery system was needed to sustain drug/GMCSF exposure at the tumour site, reduce systemic toxicity, and promote tumour…
Read the article →Clinical Cancer Research2010ResearchNon-viral Gene Delivery
Han Hd, Mangala Ls, Lee Jw, Shahzad Mmk, Kim Hs, Shen D, Nam Ej, Mora Em, Stone Rl, Lu C, Lee Sj, Roh Jw, Nick Am, Lopez-Berestein G, Sood Ak
siRNA has therapeutic potential, but in vivo delivery is limited by rapid clearance, nuclease degradation, and nonspecific distribution. A tumour-targeted, biocompatible delivery system was needed to increase intratumoral siRNA accumulation, reduce off-target effects, and enable silencing of growth-promoting genes in…
Read the article →Journal of Controlled Release2010ResearchNon-viral Gene Delivery
Luis J. Cruz, Paul J. Tacken, Remco Fokkink, Ben Joosten, Martien Cohen Stuart, Fernando Albericio, Ruurd Torensma, Carl G. Figdor
Antibody-mediated targeting of vaccine components to dendritic cells (DCs) enhances vaccine efficacy, but linking multiple antigens and immune modulators to a single antibody is limited. Slow-release PLGA particles conjugated to DC-specific antibodies could overcome this by delivering large antigen payloads and…
Read the article →Gene Therapy2010ReviewNon-viral Gene Delivery
Lam Ap, Dean Da.
The nuclear envelope remains a major barrier to successful nonviral transfection and gene therapy. After exogenous DNA is delivered to the cytoplasm, it rapidly complexes with cellular proteins that control its intracellular trafficking and nuclear import. Understanding these mechanisms is necessary to improve…
Read the article →Nature Reviews Drug Discovery2010ReviewDrug Delivery
Robby A. Petros And Joseph M. Desimone
Engineered nanoparticles have shown promise for targeted drug delivery, but first-generation systems (liposomes and polymer–drug conjugates) have not overcome all biological barriers required for effective therapy. Key barriers include opsonisation and RES clearance, inefficient cargo encapsulation and triggered…
Read the article →